Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EVOXAC

« Back to Dashboard

Evoxac is a drug marketed by Daiichi Sankyo and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in EVOXAC is cevimeline hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.

Summary for Tradename: EVOXAC

Patents:1
Applicants:1
NDAs:1
Suppliers: see list3

Pharmacology for Tradename: EVOXAC

Clinical Trials for: EVOXAC

Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia
Status: Completed Condition: Xerostomia

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
Status: Completed Condition: Dry Mouth

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
Status: Completed Condition: Dry Mouth

Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
Status: Completed Condition: Dry Mouth

Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
Status: Completed Condition: Head and Neck Cancer; Oral Complications; Radiation Toxicity

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo
EVOXAC
cevimeline hydrochloride
CAPSULE;ORAL020989Jan 11, 2000RXYes5,340,821<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: EVOXAC

Drugname Dosage Strength RLD Submissiondate
cevimeline hydrochlorideCapsules30 mgEvoxac2/27/2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:
Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc